Aim: To correlate QUS backscatter coefficient (BSC) with MRI PDFF as indicators of HS in a cohort of adults pts with NAFLD & normal controls. Methods: We conducted a prospective study derived from a cohort of consecutive pts with NAFLD (MRI PDFF > 5%) & normal controls (NC) (MRI PDFF < 5%). Both the NAFLD & the NC group this website underwent a detailed clinical research visit. Liver MRI & US was performed on the same day. MRI-PDFF was estimated & QUS measurements were made. Performance of QUS-derived BSC to diagnose HS, using

MRIPDFF > 5% as the reference standard, was evaluated by ROC analysis. Results: Among the total of 68 (67% M) pts, 29 had NAFLD (MRI PDFF range; 5.7-35.3%) & 39 were NC (MRI PDFF range; 1.1-4.6%). The mean (± SD) age & BMI of NAFLD pts vs NC was 47.8 (±13.8) vs 37.7 (±20.5) yrs, & 32.5 (±4.5) vs 25.9 ((±5.8) kg/m2, respectively. QUS BSC at 3.0 MHz ranged over two orders of magnitude from 0.0002 to 0.087 1/(cm-sr) & correlated well with MRI PDFF (R2=0.76, figure). A BSC threshold of 0.002/cm-sr provided a raw sensitivity of 97%, & specificity of 92% with an AUROC of 99% (95% CI, 95.9-99.9) for the diagnosis of HS. Conclusion: In this proof of concept study, the QUS BSC, measureable with a simple & inexpensive US technique,

can accurately detect the presence of NAFLD & quantify HS in human subjects. If validated in a larger cohort, these results may have significant implications for screening NAFLD at the level of population. Disclosures: Rohit Loomba – Consulting: Gilead Inc, Corgenix Inc;

RG7204 price Grant/Research Support: Daiichi Sankyo Inc, AGA Michael S. Middleton – Consulting: Gilead, Pfizer, Synageva, Merck, Bracco; Grant/Research Support: Isis, Genzyme, Siemens, Bayer; Stock Shareholder: General Electric Claude B. Sirlin – Advisory Committees or Review Panels: Bayer, ISIS, Bayer, ISIS; Consulting: Genzyme, Gilead, Siemens; Grant/Research Support: GE, Bayer, GE, Bayer, Pfizer; Speaking and Teaching: Bayer, Bayer The following people have nothing to 上海皓元 disclose: Abdullah Alturki, A. Han, Jessica Lam, Brandon Ang, Archana Bhatt, Jonathan Hooker, A. Shah, K. Zand, Tanya Wolfson, William D. O’Brien, Michael P. Andre Iron is implicated in the pathogenesis of liver injury and insulin resistance. Consequently iron removal by phlebotomy has been proposed as a treatment strategy for patients with non-alcoholic fatty liver disease (NAFLD). We wished to examine the impact of iron reduction by phlebotomy on liver injury, hepatic steatosis and insulin resistance in patients with NAFLD by performing a prospective 6-month randomized controlled trial. Interim results of the initial 53 completed subjects are presented. Methods: Subjects with imaging confirmed NAFLD were randomly allocated to phlebotomy plus lifestyle advice or lifestyle advice only. Phlebotomy was performed every 2-3 weeks as tolerated, aiming for a ferritin<100.